Vivek Shah - J2 Global, Inc.
Management
So maybe I'll just start with respect to the Q2 question, Shweta. So, look, I think that, again, when we were talking about this in May, we really only had April and April was really the height of the dislocation in the ad market. We quickly saw some recovery basically by the middle of May and then into June. And again, I think it's the factors I spoke about, which is performance, marketing and orientation as dollars shifted from brand advertising in the marketplace to performance that if we're going to advertise marketers we said, look, we need to generate ROI and real return on ad spend, it does benefit that we are significantly in the pharma adverts, the pharmaceutical advertising market as the Everyday Health Group which was very, very helpful. Overall, it's a very strong category and a major driver of that. As talked (00:59:19) about before, which is the marketing that's done to physicians, which in the industry exceeds the spending on marketing to patients and consumers, has gone from a physical process of sales reps visiting physical doctors' offices to entirely a digital process and our MedPage Today and associated assets are leaders in that space. So, that movement was a big driver in the overall pharma and health care performance component. And then just the retail performance marketing where we get compensated for driving traffic to online retailers, who then pay us a percentage of the ensuing transaction, in that business, what we were seeing early in the quarter were a number of retailers saying, look, we can't take the demand, don't send us the traffic we can't fulfill. Those supply chain issues were fully resolved faster than we had thought. And so, that came back entirely; that rebounded in its entirety and we're optimistic about it for the rest of the year.